AR072943A1 - Estereo isomero de metil-(2-hidroxi-5-(((2-(4-hidroxifenil)-1-metiletil)amino)etil)fenil)-acetamida, mezcla de sus isomeros, proceso de preparacion del mismo, una composicion farmaceutica que contiene a dicho carbamato y uso del mismo - Google Patents
Estereo isomero de metil-(2-hidroxi-5-(((2-(4-hidroxifenil)-1-metiletil)amino)etil)fenil)-acetamida, mezcla de sus isomeros, proceso de preparacion del mismo, una composicion farmaceutica que contiene a dicho carbamato y uso del mismoInfo
- Publication number
- AR072943A1 AR072943A1 ARP080103726A ARP080103726A AR072943A1 AR 072943 A1 AR072943 A1 AR 072943A1 AR P080103726 A ARP080103726 A AR P080103726A AR P080103726 A ARP080103726 A AR P080103726A AR 072943 A1 AR072943 A1 AR 072943A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- same
- pharmaceutical composition
- formula
- mixture
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- -1 AMINO Chemical class 0.000 title abstract 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 title 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 8
- 206010006482 Bronchospasm Diseases 0.000 abstract 2
- 230000007885 bronchoconstriction Effects 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 230000002441 reversible effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000003431 steroids Chemical class 0.000 abstract 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- 208000027771 Obstructive airways disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 229940092705 beclomethasone Drugs 0.000 abstract 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 abstract 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical group NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 abstract 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 abstract 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 abstract 1
- 229940124630 bronchodilator Drugs 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229960002714 fluticasone Drugs 0.000 abstract 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960001664 mometasone Drugs 0.000 abstract 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 abstract 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 229960005294 triamcinolone Drugs 0.000 abstract 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/16—Preparation of optical isomers
- C07C231/18—Preparation of optical isomers by stereospecific synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96643807P | 2007-08-28 | 2007-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR072943A1 true AR072943A1 (es) | 2010-10-06 |
Family
ID=40291128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080103726A AR072943A1 (es) | 2007-08-28 | 2008-08-27 | Estereo isomero de metil-(2-hidroxi-5-(((2-(4-hidroxifenil)-1-metiletil)amino)etil)fenil)-acetamida, mezcla de sus isomeros, proceso de preparacion del mismo, una composicion farmaceutica que contiene a dicho carbamato y uso del mismo |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US8501994B2 (enExample) |
| EP (1) | EP2195285B1 (enExample) |
| JP (1) | JP5468543B2 (enExample) |
| KR (1) | KR101398775B1 (enExample) |
| AR (1) | AR072943A1 (enExample) |
| AU (1) | AU2008296458B2 (enExample) |
| CA (1) | CA2696943C (enExample) |
| ES (1) | ES2684125T3 (enExample) |
| MX (1) | MX2010001978A (enExample) |
| NZ (1) | NZ583462A (enExample) |
| TW (1) | TWI505826B (enExample) |
| WO (1) | WO2009032764A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200510277A (en) * | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
| US8501994B2 (en) | 2007-08-28 | 2013-08-06 | Sunovion Pharmaceuticals Inc. | Acetamide stereoisomer |
| EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
| EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
| JP2022521600A (ja) * | 2019-02-22 | 2022-04-11 | シラ セラピューティック インコーポレイティッド | 吸入可能な治療剤 |
| CN111944855B (zh) * | 2020-09-03 | 2022-08-30 | 扬州中宝药业股份有限公司 | 一种合成(r)-1-(4-(苄氧基)-3-硝基苯基)-2-溴乙醇的方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1415256A (en) | 1972-02-05 | 1975-11-26 | Yamanouchi Pharma Co Ltd | Alpha-aminomethylbenzyl alcohol derivatives |
| US3994974A (en) * | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
| DE2366625C2 (enExample) | 1972-02-05 | 1988-06-09 | Yamanouchi Pharmaceutical Co., Ltd., Tokio/Tokyo, Jp | |
| JPS4880523A (enExample) * | 1972-02-05 | 1973-10-29 | ||
| JPS599542B2 (ja) * | 1980-06-11 | 1984-03-03 | 山之内製薬株式会社 | 新規な３−アシルアミノ−４−ヒドロキシ−α−（アラルキルアミノメチル）ベンジルアルコ−ルの製法 |
| ES2005492A6 (es) | 1987-12-23 | 1989-03-01 | Lasa Lab | Procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2((2- (4-metoxifenil)-1metiletil)amino)etil)fenil)foramida (i). |
| ES2031407A6 (es) | 1988-10-05 | 1992-12-01 | Lasa Lab | Mejoras introducidas en el objeto de la patente principal n{ 8703715 por: procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2-((2-(4-metoxifenil)-1-metiletil)amino)etil)fenil)formamida". |
| CN1083831C (zh) | 1996-01-10 | 2002-05-01 | 旭化成株式会社 | 新的三环化合物及含有它们的药物组合物 |
| DK0938467T3 (da) | 1996-11-11 | 2002-10-07 | Sepracor Inc | Fremgangsmåde til fremstilling af optisk rene isomerer af formoterol |
| US6040344A (en) * | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| US6303145B2 (en) * | 1999-05-10 | 2001-10-16 | Sepracor Inc. | (S,R) formoterol methods and compositions |
| US6472563B1 (en) * | 2001-11-09 | 2002-10-29 | Sepracor Inc. | Formoterol tartrate process and polymorph |
| US7718822B2 (en) * | 2007-08-28 | 2010-05-18 | Sepracor Inc. | Carbamate Stereoisomer |
| US8501994B2 (en) * | 2007-08-28 | 2013-08-06 | Sunovion Pharmaceuticals Inc. | Acetamide stereoisomer |
-
2008
- 2008-08-22 US US12/196,520 patent/US8501994B2/en not_active Expired - Fee Related
- 2008-08-26 TW TW097132495A patent/TWI505826B/zh not_active IP Right Cessation
- 2008-08-27 AR ARP080103726A patent/AR072943A1/es unknown
- 2008-08-28 CA CA2696943A patent/CA2696943C/en active Active
- 2008-08-28 EP EP08829102.6A patent/EP2195285B1/en not_active Not-in-force
- 2008-08-28 NZ NZ583462A patent/NZ583462A/en not_active IP Right Cessation
- 2008-08-28 ES ES08829102.6T patent/ES2684125T3/es active Active
- 2008-08-28 AU AU2008296458A patent/AU2008296458B2/en not_active Ceased
- 2008-08-28 JP JP2010523136A patent/JP5468543B2/ja not_active Expired - Fee Related
- 2008-08-28 KR KR1020107006647A patent/KR101398775B1/ko not_active Expired - Fee Related
- 2008-08-28 WO PCT/US2008/074653 patent/WO2009032764A1/en not_active Ceased
- 2008-08-28 MX MX2010001978A patent/MX2010001978A/es active IP Right Grant
-
2013
- 2013-07-03 US US13/934,996 patent/US8664441B2/en active Active
-
2014
- 2014-01-17 US US14/157,793 patent/US9040588B2/en active Active
-
2015
- 2015-04-22 US US14/692,843 patent/US9499476B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2696943C (en) | 2015-05-26 |
| US9040588B2 (en) | 2015-05-26 |
| CA2696943A1 (en) | 2009-03-12 |
| US20140135300A1 (en) | 2014-05-15 |
| AU2008296458A1 (en) | 2009-03-12 |
| US8501994B2 (en) | 2013-08-06 |
| US9499476B2 (en) | 2016-11-22 |
| WO2009032764A1 (en) | 2009-03-12 |
| TWI505826B (zh) | 2015-11-01 |
| EP2195285A1 (en) | 2010-06-16 |
| KR101398775B1 (ko) | 2014-05-27 |
| US20130296607A1 (en) | 2013-11-07 |
| KR20100047333A (ko) | 2010-05-07 |
| TW200913984A (en) | 2009-04-01 |
| NZ583462A (en) | 2012-03-30 |
| JP5468543B2 (ja) | 2014-04-09 |
| JP2010538010A (ja) | 2010-12-09 |
| EP2195285B1 (en) | 2018-08-01 |
| US20150225334A1 (en) | 2015-08-13 |
| MX2010001978A (es) | 2010-05-27 |
| US8664441B2 (en) | 2014-03-04 |
| ES2684125T3 (es) | 2018-10-01 |
| AU2008296458B2 (en) | 2014-01-16 |
| US20090060922A1 (en) | 2009-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072943A1 (es) | Estereo isomero de metil-(2-hidroxi-5-(((2-(4-hidroxifenil)-1-metiletil)amino)etil)fenil)-acetamida, mezcla de sus isomeros, proceso de preparacion del mismo, una composicion farmaceutica que contiene a dicho carbamato y uso del mismo | |
| EP2968208B1 (en) | Treatment of cataplexy | |
| MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
| CA2666612A1 (en) | Methods, compositions, and formulations for the treatment of thyroid eye disease | |
| US20170151209A1 (en) | Methods for treating bipolar disorder | |
| BR112013027028A2 (pt) | preparo de gadobutrol de alta pureza | |
| BR112014004845A2 (pt) | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| NZ606548A (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
| WO2012116290A3 (en) | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| BR112014004963A2 (pt) | sal de colina do composto anti-inflamatório ciclobutanodiona substituído | |
| BR112014029016A8 (pt) | derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| RU2013106866A (ru) | Фармацевтические композиции | |
| BR112014009927A2 (pt) | "derivado de azol, composição farmacêutica que o compreende e uso do mesmo" | |
| BR112012017691A2 (pt) | nova composição | |
| KR101621676B1 (ko) | 천식의 병세악화를 예방 및/또는 치료하기 위한 포르모테롤 및 베클로메타손 디프로피오네이트를 포함하는 조성의 용도 | |
| BR112014001369A2 (pt) | derivados de ácido hidroxâmico de heteroarila e uso dos mesmos no tratamento, melhora ou prevenção de doença viral | |
| CL2013003630A1 (es) | Formulacion farmaceutica liquida que comprende nitisinona y un tampon de acido citrico que tien un ph en el rango de 2,5 a 3,5, de preferencia 3,0; y su uso para el tratamiento de tirosemia, enfermedad de parkinson, depresion, entre otros. | |
| BR112013018598A2 (pt) | composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca | |
| JP2010538010A5 (enExample) | ||
| AR071045A1 (es) | Estereo isomero de metil-( 2-hidroxi-5- (((2-(4-hidroxifenil)-1-metiletil) amino)etil)fenil)- carbamato, mezcla de sus isomeros, proceso de preparacion del mismo, una composicion farmaceutica que contiene a dicho carbamato y uso del mismo | |
| JP2016537432A5 (enExample) | ||
| JP2015534990A5 (enExample) | ||
| UY32486A (es) | Tratamiento del cáncer de páncreas | |
| BR112022009533A2 (pt) | Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica | |
| JP2020533402A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |